share_log

Ainos To Initiate Clinical Study Of New VELDONA-Based Animal Drug, Expanding Potential Market

Benzinga ·  May 15 08:18
  • Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the initiation of a clinical study for a new potential VELDONA-based drug for pet disease. The study is aimed at evaluating the clinical efficacy of low-dose oral interferons in treating feline chronic gingivostomatitis ("FCGS"), a serious and chronic painful oral disease characterized by inflammation or abnormal proliferation in the oral cavity.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment